Singer Michael C, Marchal Francis, Angelos Peter, Bernet Vic, Boucai Laura, Buchholzer Samanta, Burkey Brian, Eisele David, Erkul Evren, Faure Frederic, Freitag Suzanne K, Gillespie Marion Boyd, Harrell Richard Mack, Hartl Dana, Haymart Megan, Leffert Jonathan, Mandel Susan, Miller Barbra S, Morris John, Pearce Elizabeth N, Rahmati Rahmatullah, Ryan William R, Schaitkin Barry, Schlumberger Martin, Stack Brendan C, Van Nostrand Doug, Wong Ka Kit, Randolph Gregory
Department of Otolaryngology - Head and Neck Surgery, Henry Ford Health System, Detroit, Michigan, USA.
Department of Otolaryngology - Head and Neck Surgery, Geneva University Hospital, Geneva, Switzerland.
Head Neck. 2020 Nov;42(11):3446-3459. doi: 10.1002/hed.26417. Epub 2020 Aug 19.
Postoperative radioactive iodine (RAI) administration is widely utilized in patients with differentiated thyroid cancer. While beneficial in select patients, it is critical to recognize the potential negative sequelae of this treatment. The prevention, diagnosis, and management of the salivary and lacrimal complications of RAI exposure are addressed in this consensus statement.
A multidisciplinary panel of experts was convened under the auspices of the American Head and Neck Society Endocrine Surgery and Salivary Gland Sections. Following a comprehensive literature review to assess the current best evidence, this group developed six relevant consensus recommendations.
Consensus recommendations on RAI were made in the areas of patient assessment, optimal utilization, complication prevention, and complication management.
Salivary and lacrimal complications secondary to RAI exposure are common and need to be weighed when considering its use. The recommendations included in this statement provide direction for approaches to minimize and manage these complications.
术后放射性碘（RAI）治疗在分化型甲状腺癌患者中广泛应用。虽然对特定患者有益，但认识到这种治疗潜在的负面后果至关重要。本共识声明阐述了放射性碘暴露导致的唾液腺和泪腺并发症的预防、诊断及管理。
在美国头颈协会内分泌外科和唾液腺分会的支持下，召集了一个多学科专家小组。在全面回顾文献以评估当前最佳证据后，该小组制定了六项相关共识建议。
在患者评估、最佳利用、并发症预防和并发症管理等方面就放射性碘治疗达成了共识建议。
放射性碘暴露继发的唾液腺和泪腺并发症很常见，在考虑使用放射性碘治疗时需要权衡。本声明中的建议为尽量减少和管理这些并发症的方法提供了指导。
